MedTrace Logo

A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension

NCT00779181 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2008-12-17

No results posted yet for this study

Summary

The purpose of this study is to determine a safe and effective dose of ADX415 for the treatment of hypertension.

Conditions

Interventions

DRUG

ADX415

ADX415 taken three times a day to achieve a high total daily dose

DRUG

ADX415

ADX415 taken three times a day to achieve a mid level total daily dose

DRUG

ADX415

ADX415 taken three times a day to achieve a low total daily dose

DRUG

Placebo

Placebo taken three times a day

Sponsors & Collaborators

  • Addrenex Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Moise Khayrallah, PhD · Addrenex Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00779181 on ClinicalTrials.gov